Savara (SVRA) Revenue & Revenue Breakdown
Savara Revenue Highlights
0
Latest Revenue (Q)
$272.00K
Savara Revenue by Period
Savara Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | - | 100.00% |
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $257.00K | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | -100.00% |
2016-12-31 | $400.00K | 740640.74% |
2015-12-31 | $54.00 | -96.51% |
2014-12-31 | $1.55K | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2011-12-31 | - | -100.00% |
2010-12-31 | $488.96K | 62.99% |
2009-12-31 | $300.00K | -40.00% |
2008-12-31 | $500.00K | - |
2007-12-31 | $500.00K | 100.00% |
2006-12-31 | - | -100.00% |
2005-12-31 | $496.06K | 100.00% |
2004-12-31 | - | 100.00% |
2003-12-31 | - | 100.00% |
2002-12-31 | - | 100.00% |
2001-12-31 | - | 100.00% |
2000-12-31 | - | - |
Savara generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Savara Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-12-31 | $272.00K | 100.00% |
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | 100.00% |
2023-12-31 | - | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $1.00K | -99.61% |
2020-09-30 | $256.00K | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | -100.00% |
2017-12-31 | $-94.00K | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | -100.00% |
2017-03-31 | $94.00K | 13.25% |
2016-12-31 | $83.00K | 84.44% |
2016-09-30 | $45.00K | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2012-09-30 | - | 100.00% |
2012-06-30 | - | 100.00% |
2012-03-31 | - | 100.00% |
2011-12-31 | - | 100.00% |
2011-09-30 | - | 100.00% |
2011-06-30 | - | 100.00% |
2011-03-31 | - | -100.00% |
2010-12-31 | $488.96K | 100.00% |
2010-09-30 | - | 100.00% |
2010-06-30 | - | 100.00% |
2010-03-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2009-09-30 | - | 100.00% |
2009-06-30 | - | -100.00% |
2009-03-31 | $300.00K | 100.00% |
2008-12-31 | - | 100.00% |
2008-09-30 | - | 100.00% |
2008-06-30 | - | 100.00% |
2008-03-31 | - | 100.00% |
2007-12-31 | - | - |
Savara generated $272.00K in revenue during Q4 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Savara Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
TRDA | Entrada Therapeutics | $210.78M | $37.40M |
ACLX | Arcellx | $107.94M | $15.27M |
ANAB | AnaptysBio | $91.28M | $43.11M |
FENC | Fennec Pharmaceuticals | $47.54M | $7.92M |
STOK | Stoke Therapeutics | $36.55M | $22.61M |
XOMA | XOMA | $28.49M | $15.91M |
XLO | Xilio Therapeutics | $6.34M | $1.72M |
CRNX | Crinetics Pharmaceuticals | $1.04M | - |
IKNA | Ikena Oncology | - | - |
RZLT | Rezolute | - | - |
GPCR | Structure Therapeutics | - | - |
ALXO | ALX Oncology | - | - |
SVRA | Savara | - | $272.00K |
RVMD | Revolution Medicines | - | - |
EWTX | Edgewise Therapeutics | - | - |
TARA | Protara Therapeutics | - | - |
AVTE | Aerovate Therapeutics | - | - |
KZR | Kezar Life Sciences | - | - |
DYN | Dyne Therapeutics | - | - |
SRRK | Scholar Rock | - | - |
TPST | Tempest Therapeutics | - | $486.00K |
PTIX | Protagenic Therapeutics | - | - |